𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A pediatric oncology group phase II study

✍ Scribed by Faith H. Kung; Charles B. Pratt; Roger A. Vega; Norman Jaffe; Douglas Strother; Molly Schwenn; Ruprecht Nitschke; Alan C. Homans; C. Tate Holbrook; Barry Golembe; Mark Bernstein; Jeffrey P. Krischer

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
509 KB
Volume
71
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Background. The prognosis for children with recurrent or resistant malignant solid tumors remains dismal. More effective rescue therapy is needed for these children.

Methods. Between August 1987 and November 1990, 311 children with recurrent or resistant malignant solid tumors were treated by investigators in the Pediatric Oncology Group with intravenous infusions of 2.0 g/m2 of ifosfamide and 100 mg/m2 of etoposide (VP-16) plus mesna as uroprotection three times daily, with courses being repeated every 14-21 days for as long as the patients responded to therapy.

Results. Seventy-four percent of the 294 assessable patients entered in the study had metastatic disease and previously had been treated heavily. The complete re-From the

πŸ“œ SIMILAR VOLUMES

Ifosfamide/Carboplatin/Etoposide (ICE),
Ifosfamide/Carboplatin/Etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood: A Pediatric Oncology Group phase II study
✍ Kung, Faith H.; Harris, Michael B.; Krischer, Jeffrey P. πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 41 KB πŸ‘ 2 views

nary observations on ICE as salvaging therapy for refractory NHL are encouraging. More study is needed to confirm our findings and to delineate which subtypes of NHL are most responsive to ICE therapy.

Phase II study of ifosfamide in childhoo
Phase II study of ifosfamide in childhood brain tumors: A report by the French society of pediatric oncology (SFOP)
✍ Chastagner, Pascal ;Sommelet-Olive, DaniΓ¨le ;Kalifa, Chantal ;Brunat-Mentigny, M πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 482 KB

## Abstract Forty‐two evaluable pediatric patients with a variety of recurrent primary brain tumors participated in a phase II ifosfamide trial. Their mean age was 10 years. All patients were treated with ifosfamide, 3 g/m^2^/day for 2 days every 2 weeks. Response was assessed on clinical and radio

5-fluorouracil and cis-platinum in the t
5-fluorouracil and cis-platinum in the treatment of refractory solid tumors: A pediatric oncology group phase I β€” II study
✍ Land, Vita J. ;Dyment, Paul G. ;Starling, Kenneth ;Strandjord, Sarah E. ;Chan, R πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 189 KB

## Abstract Eleven patients with osteogenic sarcoma (9), Hodgkin disease (1), and mesenchymal sarcoma (1), were treated with 5‐fluorouracil (5‐FU) and cisplatin (DDP). Myelosuppression and vomiting of variable degrees occurred in all. No responses were seen.

Phase II investigation of docetaxel in p
Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors : A report from the Children's Oncology Group
✍ Ted Zwerdling; Mark Krailo; Philip Monteleone; Rebecca Byrd; Judith Sato; Rose D πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 106 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Docetaxel, which is an antitubulin agent, has demonstrable activity against murine and human tumors. The current study was designed to determine response rates to docetaxel in various strata of recurrent solid tumors of childhood and to assess toxicity in a group of patie